Understanding CD8+ T-cell responses toward the native and alternate HLA-A∗02:01-restricted WT1 epitope

Clinical and Translational Immunology

Volumn 6, Issue 3, 2017, Pages

  Nguyen, Thi H O ^a   Tan, Amabel C L ^a,b   Xiang, Sue D ^b,c   Goubier, Anne ^b   Harland, Kim L ^a   Clemens, E Bridie ^a   Plebanski, Magdalena ^b,c   Kedzierska, Katherine ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b PX Biosolutions Pty Ltd   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; EPITOPE; HLA A ANTIGEN; HLA A2 ANTIGEN; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; WT1 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN BINDING; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS REACTION; CYTOKINE RELEASE; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENIC MOUSE;

EID: 85040972536     PISSN: None     EISSN: 20500068     Source Type: Journal    
DOI: 10.1038/cti.2017.4     Document Type: Article

References (48)

1. Call KM, Glaser T, Ito CY, Buckler AJ, Pelletier J, Haber DA et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 1990; 60: 509-520.
2. Gessler M, Poustka A, Cavenee W, Neve RL, Orkin SH, Bruns GA. Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping. Nature 1990; 343: 774-778.
3. Jomgeow T, Oji Y, Tsuji N, Ikeda Y, Ito K, Tsuda A et al. Wilms' tumor gene WT1 17AA (-)/KTS(-) isoform induces morphological changes and promotes cell migration and invasion in vitro. Cancer Sci 2006; 97: 259-270.
4. Nakatsuka S, Oji Y, Horiuchi T, Kanda T, Kitagawa M, Takeuchi T et al. Immunohis-tochemical detection of WT1 protein in a variety of cancer cells. Mod Pathol 2006; 19: 804-814.
5. Oka Y, Tsuboi A, Oji Y, Kawase I, Sugiyama H. WT1 peptide vaccine for the treatment of cancer. Curr Opin Immunol 2008; 20: 211-220.
6. Oka Y, Udaka K, Tsuboi A, Elisseeva OA, Ogawa H, Aozasa K et al. Cancer immunotherapy targeting Wilms' tumor gene WT1 product. J Immunol 2000; 164: 1873-1880.
7. Nakajima H, Kawasaki K, Oka Y, Tsuboi A, Kawakami M, Ikegame K et al. WT1 peptide vaccination combined with BCG-CWS is more efficient for tumor eradication than WT1 peptide vaccination alone. Cancer Immunol Immunother 2004; 53: 617-624.
8. Makita M, Hiraki A, Azuma T, Tsuboi A, Oka Y, Sugiyama H et al. Antilung cancer effect of WT1-specific cytotoxic T lymphocytes. Clin Cancer Res 2002; 8: 2626-2631.
9. Oka Y, Tsuboi A, Murakami M, Hirai M, Tominaga N, Nakajima H et al. Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis. Int J Hematol 2003; 78: 56-61.
10. Oka Y, Tsuboi A, Taguchi T, Osaki T, Kyo T, Nakajima H et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA 2004; 101: 13885-13890.
11. Izumoto S, Tsuboi A, Oka Y, Suzuki T, Hashiba T, Kagawa N et al. Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme. J Neurosurg 2008; 108: 963-971.
12. Hashii Y, Sato-Miyashita E, Matsumura R, Kusuki S, Yoshida H, Ohta H et al. WT1 peptide vaccination following allogeneic stem cell transplantation in pediatric leukemic patients with high risk for relapse: successful maintenance of durable remission. Leukemia 2012; 26: 530-532.
13. Sawada A, Inoue M, Kondo O, Yamada-Nakata K, Ishihara T, Kuwae Y et al. Feasibility of cancer immunotherapy with WT1 peptide vaccination for solid and hematological malignancies in children. Pediatr Blood Cancer 2016; 63: 234-241.
14. Robinson J, Waller MJ, Parham P, de Groot N, Bontrop R, Kennedy LJ et al. IMGT/HLA and IMGT/MHC: sequence databases for the study of the major histocompatibility complex. Nucleic Acids Res 2003; 31: 311-314.
15. Van Tendeloo VF, Van de Velde A, Van Driessche A, Cools N, Anguille S, Ladell K et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci USA 2010; 107: 13824-13829.
16. ∗0201-restricted epitopes derived from Wilms' tumor 1 protein in patients with leukemia and healthy donors: identification, quantification, and characterization. Clin Cancer Res 2005; 11: 8799-8807.
17. Shah NN, Loeb DM, Khuu H, Stroncek D, Ariyo T, Raffeld M et al. Induction of immune response after allogeneic Wilms' tumor 1 dendritic cell vaccination and donor lymphocyte infusion in patients with hematologic malignancies and posttransplantation relapse. Biol Blood Marrow Transplant 2016; 22: 2149-2154.
18. Rezvani K, Yong AS, Mielke S, Savani BN, Musse L, Superata J et al. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 2008; 111: 236-242.
19. Rezvani K, Yong AS, Mielke S, Jafarpour B, Savani BN, Le RQ et al. Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies. Haematologica 2011; 96: 432-440.
20. Uttenthal B, Martinez-Davila I, Ivey A, Craddock C, Chen F, Virchis A et al. Wilms' tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses. Br J Haematol 2014; 164: 366-375.
21. Pinilla-Ibarz J, May RJ, Korontsvit T, Gomez M, Kappel B, Zakhaleva V et al. Improved human T-cell responses against synthetic HLA-0201 analog peptides derived from the WT1 oncoprotein. Leukemia 2006; 20: 2025-2033.
22. Maslak PG, Dao T, Krug LM, Chanel S, Korontsvit T, Zakhaleva V et al. Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. Blood 2010; 116: 171-179.
23. Krug LM, Dao T, Brown AB, Maslak P, Travis W, Bekele S et al. WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer. Cancer Immunol Immunother 2010; 59: 1467-1479.
24. Kotturi MF, Scott I, Wolfe T, Peters B, Sidney J, Cheroutre H et al. Naive precursor frequencies and MHC binding rather than the degree of epitope diversity shape CD8+ T cell immunodominance. J Immunol 2008; 181: 2124-2133.
25. Obar JJ, Khanna KM, Lefrancois L. Endogenous naive CD8+ T cell precursor frequency regulates primary and memory responses to infection. Immunity 2008; 28: 859-869.
26. La Gruta NL, Kedzierska K, Pang K, Webby R, Davenport M, Chen W et al. A virus-specific CD8+ T cell immunodominance hierarchy determined by antigen dose and precursor frequencies. Proc Natl Acad Sci USA 2006; 103: 994-999.
27. Valkenburg SA, Gras S, Guillonneau C, La Gruta NL, Thomas PG, Purcell AW et al. Protective efficacy of cross-reactive CD8+ T cells recognising mutant viral epitopes depends on peptide-MHC-I structural interactions and T cell activation threshold. PLoS Pathog 2010; 6: e1001039.
28. Alanio C, Lemaitre F, Law HK, Hasan M, Albert ML. Enumeration of human antigen-specific naive CD8+ T cells reveals conserved precursor frequencies. Blood 2010; 115: 3718-3725.
29. ∗0201-restricted CD8+ T-cell immunity against influenza viruses. Proc Natl Acad Sci USA 2016; 113: 4440-4445.
30. Cukalac T, Valkenburg SA, La Gruta NL, Turner SJ, Doherty PC, Kedzierska K. Multiplexed combinatorial tetramer staining in a mouse model of virus infection. J Immunol Methods 2010; 360: 157-161.
31. La Gruta NL, Rothwell WT, Cukalac T, Swan NG, Valkenburg SA, Kedzierska K et al. Primary CTL response magnitude in mice is determined by the extent of naive T cell recruitment and subsequent clonal expansion. J Clin Invest 2010; 120: 1885-1894.
32. Quinn KM, Zaloumis SG, Cukalac T, Kan WT, Sng XY, Mirams M et al. Heightened self-reactivity associated with selective survival, but not expansion, of naive virus-specific CD8+ T cells in aged mice. Proc Natl Acad Sci USA 2016; 113: 1333-1338.
33. Rauscher FJ 3rd. The WT1 Wilms tumor gene product: a developmentally regulated transcription factor in the kidney that functions as a tumor suppressor. FASEB J 1993; 7: 896-903.
34. Firat H, Cochet M, Rohrlich PS, Garcia-Pons F, Darche S, Danos O et al. Comparative analysis of the CD8(+) T cell repertoires of H-2 class I wild-type/HLA-A2.1 and H-2 class I knockout/HLA-A2.1 transgenic mice. Int Immunol 2002; 14: 925-934.
35. Pascolo S, Bervas N, Ure JM, Smith AG, Lemonnier FA, Perarnau B. HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice. J Exp Med 1997; 185: 2043-2051.
36. Chaise C, Buchan SL, Rice J, Marquet J, Rouard H, Kuentz M et al. DNA vaccination induces WT1-specific T-cell responses with potential clinical relevance. Blood 2008; 112: 2956-2964.
37. Schmied S, Gostick E, Price DA, Abken H, Assenmacher M, Richter A. Analysis of the functional WT1-specific T-cell repertoire in healthy donors reveals a discrepancy between CD4(+) and CD8(+) memory formation. Immunology 2015; 145: 558-569.
38. Najima Y, Tomizawa-Murasawa M, Saito Y, Watanabe T, Ono R, Ochi T et al. Induction of WT1-specific human CD8+ T cells from human HSCs in HLA class I Tg NOD/SCID/IL2rgKO mice. Blood 2016; 127: 722-734.
39. Kirksey TJ, Pogue-Caley RR, Frelinger JA, Collins EJ. The structural basis for the increased immunogenicity of two HIV-reverse transcriptase peptide variant/class I major histocompatibility complexes. J Biol Chem 1999; 274: 37259-37264.
40. ∗0201: implications for WT1-based cancer therapeutics. Mol Immunol 2010; 47: 2519-2524.
41. Al Qudaihi G, Lehe C, Negash M, Al-Alwan M, Ghebeh H, Mohamed SY et al. Enhancement of lytic activity of leukemic cells by CD8+ cytotoxic T lymphocytes generated against a WT1 peptide analogue. Leuk Lymphoma 2009; 50: 260-269.
42. Nguyen TH, Sullivan LC, Kotsimbos TC, Schwarer AP, Mifsud NA. Cross-presentation of HCMV chimeric protein enables generation and measurement of polyclonal T cells. Immunol Cell Biol 2010; 88: 676-684.
43. Chua BY, Zeng W, Jackson DC. Synthesis of toll-like receptor-2 targeting lipopeptides as self-adjuvanting vaccines. Methods Mol Biol 2008; 494: 247-261.
44. Tan AC, La Gruta NL, Zeng W, Jackson DC. Precursor frequency and competition dictate the HLA-A2-restricted CD8+ T cell responses to influenza A infection and vaccination in HLA-A2.1 transgenic mice. J Immunol 2011; 187: 1895-1902.
45. Dash P, McClaren JL, Oguin TH 3rd, Rothwell W, Todd B, Morris MY et al. Paired analysis of TCRalpha and TCRbeta chains at the single-cell level in mice. J Clin Invest 2011; 121: 288-295.
46. Cukalac T, Kan WT, Dash P, Guan J, Quinn KM, Gras S et al. Paired TCRalphabeta analysis of virus-specific CD8(+) T cells exposes diversity in a previously defined 'narrow' repertoire. Immunol Cell Biol 2015; 93: 804-814.
47. Brochet X, Lefranc MP, Giudicelli V. IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. Nucleic Acids Res 2008; 36: W503-W508.
48. Folch G, Scaviner D, Contet V, Lefranc MP. Protein displays of the human T cell receptor alpha, beta, gamma and delta variable and joining regions. Exp Clin Immunogenet 2000; 17: 205-215.